Key result
Direct delivery of cisplatin via 68 chronically implanted catheters halted tumor progression initially, but the tumor recurred and the patient died 6 months after treatment.
Why the study?
Does direct delivery of cisplatin via multiple chronically implanted catheters improve outcomes in a patient with recurrent malignant glioma?
Population
1 patient with recurrent malignant glioma
Design
Case_report
Follow-up
6 months
Authors
Loading...
May warrant further study of chronic catheter-based cisplatin delivery; does not support clinical adoption in recurrent glioma.
Case Report (n=1)
Does direct delivery of cisplatin via multiple chronically implanted catheters improve outcomes in a patient with recurrent malignant glioma?
Direct delivery of cisplatin via multiple chronically implanted catheters halted tumor progression temporarily in a patient with recurrent malignant glioma, with no side effects, though the patient died 6 months later.
Bouvier et al. (1987) conducted a case report in Recurrent malignant glioma (n=1). Cisplatin delivered directly into the tumor via 68 small catheters was evaluated on Tumor progression and survival. Direct delivery of cisplatin via 68 chronically implanted catheters halted tumor progression initially, but the tumor recurred and the patient died 6 months after treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: